In a filing, Apellis Pharmaceuticals Inc revealed its Officer Watson David O. acquired Company’s shares for reported $93850.0 on Jun 16 ’25. In the deal valued at $18.77 per share,5,000 shares were bought.
Then, Townsend Adam J. bought 220,961 shares, generating $3,924,267 in total proceeds.
Before that, Chopas James George sold 183 shares. Apellis Pharmaceuticals Inc shares valued at $4,543 were divested by the VP/Chief Accounting Officer at a price of $24.82 per share. As a result of the transaction, Chopas James George now holds 47,955 shares, worth roughly $0.85 million.
Raymond James downgraded its Apellis Pharmaceuticals Inc [APLS] rating to an Outperform from a a Strong buy in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. Cantor Fitzgerald began covering APLS with “an Overweight” recommendation on April 29, 2025. Goldman revised its rating on December 17, 2024. It rated APLS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -2.95% to $17.76. Over the last five days, the stock has lost -9.30%. Apellis Pharmaceuticals Inc shares have fallen nearly -44.34% since the year began. Nevertheless, the stocks have fallen -58.27% over the past one year. While a 52-week high of $43.15 was reached on 01/07/25, a 52-week low of $16.10 was recorded on 05/15/25.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 17.54, which if violated will result in even more drops to 17.33. On the upside, there is a resistance level at 18.13. A further resistance level may holdings at 18.51.
The most recent change occurred on November 21, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $31 price target.
